Comprehensive Characterization of a Novel Bacteriophage, vB_VhaS_MAG7 against a Fish Pathogenic Strain of Vibrio harveyi and Its In Vivo Efficacy in Phage Therapy Trials
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24098200 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Stavros Droubogiannis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Marine Biology, Biotechnology & Aquaculture, Hellenic Centre for Marine Research, 71500 Heraklion, Greece. Hauptthemen laut MEDLINE: Bacteriophages, Phage Therapy, Vibrio, Bacterial Infections. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ROBUST-Prevention of Vibriosis caused by Vibrio harveyi with innovative tools, Greek General Secretariat of Research and Technology under the Operational Program Competitiveness, Entrepreneurship and Innovation 2014–2020.
Abstract (Originalsprache)
Vibrio harveyi, a significant opportunistic marine pathogen, has been a challenge to the aquaculture industry, leading to severe economical and production losses. Phage therapy has been an auspicious approach in controlling such bacterial infections in the era of antimicrobial resistance. In this study, we isolated and fully characterized a novel strain-specific phage, vB_VhaS_MAG7, which infects V. harveyi MM46, and tested its efficacy as a therapeutic agent in challenged gilthead seabream larvae. vB_VhaS_MAG7 is a tailed bacteriophage with a double-stranded DNA of 49,315 bp. No genes linked with virulence or antibiotic resistance were harbored in the genome. The phage had a remarkably large burst size of 1393 PFU cell−1 and showed strong lytic ability in in vitro assays. When applied in phage therapy trials in challenged gilthead seabream larvae, vB_VhaS_MAG7 was capable of improving the survival of the larvae up to 20%. Due to its distinct features and safety, vB_VhaS_MAG7 is considered a suitable candidate for applied phage therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Marine Biology, Biotechnology & Aquaculture, Hellenic Centre for Marine Research, 71500 Heraklion, Greece.
- Laboratory of Molecular Biology, Department of Biotechnology, School of Food, Biotechnology and Development, Agricultural University of Athens, 11855 Athens, Greece.
ORCID-Profile: Stavros Droubogiannis, Dimitrios Skliros, Pantelis Katharios
Förderung
- ROBUST-Prevention of Vibriosis caused by Vibrio harveyi with innovative tools
- Greek General Secretariat of Research and Technology under the Operational Program Competitiveness, Entrepreneurship and Innovation 2014–2020
Zitieren
APA
Droubogiannis, S., Pavlidi, L., Skliros, D., Flemetakis, E., & Katharios, P. (2023). Comprehensive Characterization of a Novel Bacteriophage, vB_VhaS_MAG7 against a Fish Pathogenic Strain of Vibrio harveyi and Its In Vivo Efficacy in Phage Therapy Trials. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098200
Vancouver
Droubogiannis S, Pavlidi L, Skliros D, Flemetakis E, Katharios P. Comprehensive Characterization of a Novel Bacteriophage, vB_VhaS_MAG7 against a Fish Pathogenic Strain of Vibrio harveyi and Its In Vivo Efficacy in Phage Therapy Trials. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098200
BibTeX
@article{Droubogiannis2023,
author = {Droubogiannis, Stavros and Pavlidi, Lydia and Skliros, Dimitrios and Flemetakis, Emmanouil and Katharios, Pantelis},
title = {Comprehensive Characterization of a Novel Bacteriophage, vB_VhaS_MAG7 against a Fish Pathogenic Strain of Vibrio harveyi and Its In Vivo Efficacy in Phage Therapy Trials},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24098200}
}
EUVIMED